{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T14:29:21Z","timestamp":1786544961645,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1038\/ajg.2010.125","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T10:38:53Z","timestamp":1275561533000},"page":"1227-1230","source":"Crossref","is-referenced-by-count":14,"title":["An Evidence-Based Treatment Algorithm for IBS Based on a Bacterial\/SIBO Hypothesis: Part 2"],"prefix":"10.14309","volume":"105","author":[{"given":"Mark","family":"Pimentel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-3-20210210","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/ajg.2009.678","article-title":"Evaluating a bacterial hypothesis in IBS using a modification of Kochs postulates: Part 1.","volume":"105","author":"Pimentel","year":"2010","journal-title":"Am J Gastroenterology"},{"key":"R2-3-20210210","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/gut.2006.108712","article-title":"Altered counts of small bowel bacteria in patients with irritable bowel syndrome.","volume":"56","author":"Posserud","year":"2007","journal-title":"Gut"},{"key":"R3-3-20210210","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"R4-3-20210210","first-page":"412","article-title":"Normalization of lactulose breath testing correlates with symptom improvement in irritable bowel syndrome: a double-blind, randomized, placebo-controlled study.","volume":"98","author":"Pimentel","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R5-3-20210210","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/j.1572-0241.2005.40795.x","article-title":"Detection of bacterial overgrowth in IBS using the lactulose H2 breath test: comparison with 14C-D-xylose and healthy controls.","volume":"100","author":"Walters","year":"2005","journal-title":"Am J Gastroenterol"},{"key":"R6-3-20210210","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1111\/j.1365-2036.2005.02493.x","article-title":"Abnormal breath tests to lactose, fructose and sorbitol in irritable bowel syndrome may be explained by small intestinal bacterial overgrowth.","volume":"21","author":"Nucera","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R7-3-20210210","first-page":"A460","article-title":"Evaluating the role of small intestinal bacterial overgrowth (SIBO) in diarrhea predominant irritable bowel syndrome (IBS-D) patients utilizing the glucose breath test (gbt).","volume":"128","author":"McCallum","year":"2005","journal-title":"Gastroenterology"},{"key":"R8-3-20210210","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/j.1365-2036.2005.02690.x","article-title":"Lauritano EC et al Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome.","volume":"22","author":"Lupascu","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"R9-3-20210210","first-page":"89","article-title":"Small intestine bacterial overgrowth in irritable bowel syndrome: a retrospective study with rifaximin.","volume":"52","author":"Cuoco","year":"2006","journal-title":"Minerva Gastroenterol Dietol"},{"key":"R10-3-20210210","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0016-5085(82)80186-8","article-title":"Bowel patterns among subjects not seeking health care.","volume":"83","author":"Drossman","year":"1982","journal-title":"Gastroenterology"},{"key":"R11-3-20210210","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/0016-5085(80)90142-0","article-title":"Functional bowel disorders in apparently healthy people.","volume":"79","author":"Thompson","year":"1980","journal-title":"Gastroenterology"},{"key":"R12-3-20210210","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10620-007-9839-8","article-title":"Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS.","volume":"53","author":"Yang","year":"2008","journal-title":"Dig Dis Sci"},{"key":"R13-3-20210210","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1046\/j.1365-2036.2000.00751.x","article-title":"Rifaximin versus chlortetracycline in the short-term treatment of small intestinal bacterial overgrowth.","volume":"14","author":"Di Stefano","year":"2000","journal-title":"Aliment Pharmacol Ther"},{"key":"R14-3-20210210","doi-asserted-by":"crossref","first-page":"557","DOI":"10.7326\/0003-4819-145-8-200610170-00004","article-title":"The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome.","volume":"145","author":"Pimentel","year":"2006","journal-title":"Ann Intern Med"},{"key":"R15-3-20210210","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1111\/j.1572-0241.2006.00458.x","article-title":"A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence.","volume":"101","author":"Sharara","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R16-3-20210210","doi-asserted-by":"crossref","first-page":"A545","DOI":"10.1016\/S0016-5085(08)62544-5","article-title":"Rifaximin for the treatment of diarrhea-associated irritable bowel syndrome: short term treatment leading to long term sustained response.","volume":"134","author":"Lembo","year":"2008","journal-title":"Gastroenterology"},{"key":"R17-3-20210210","doi-asserted-by":"crossref","first-page":"S64","DOI":"10.1016\/S0016-5085(10)60292-2","article-title":"Rifaximin treatment for 2 weeks provides acute and sustained relief over 12 weeks of IBS symptoms in non-constipated irritable bowel syndrome: results from 2 North American phase 3 trials (Target 1 and Target 2).","volume":"138","author":"Pimentel","year":"2010","journal-title":"Gastroenterology"},{"key":"R18-3-20210210","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1053\/j.gastro.2005.11.061","article-title":"Functional bowel disorders.","volume":"130","author":"Longstreth","year":"2006","journal-title":"Gastroenterology"},{"key":"R19-3-20210210","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1111\/j.1572-0241.2007.01072.x","article-title":"The degree of breath methane production in IBS correlates with the severity of constipation.","volume":"102","author":"Chatterjee","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R20-3-20210210","doi-asserted-by":"crossref","first-page":"G1089","DOI":"10.1152\/ajpgi.00574.2004","article-title":"Methane, a gas produced by enteric bacteria, slows intestinal transit and augments ileal contractile activity.","volume":"290","author":"Pimentel","year":"2006","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R21-3-20210210","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s10620-006-9104-6","article-title":"Neomycin improves constipation-predominant irritable bowel syndrome in a fashion that is dependent on the presence of methane gas: subanalysis of a double-blind randomized controlled study.","volume":"51","author":"Pimentel","year":"2006","journal-title":"Dig Dis Sci"},{"key":"R23-3-20210210","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10620-009-0778-4","article-title":"Evaluating breath methane as a diagnostic test for constipation-predominant IBS.","volume":"55","author":"Hwang","year":"2010","journal-title":"Dig Dis Sci"},{"key":"R25-3-20210210","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1023\/A:1021039032413","article-title":"Lower frequency of MMC is found in IBS subjects with abnormal lactulose breath test, suggesting bacterial overgrowth.","volume":"47","author":"Pimentel","year":"2002","journal-title":"Dig Dis Sci"},{"key":"R26-3-20210210","first-page":"435","article-title":"Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.","volume":"5","author":"Pimentel","year":"2009","journal-title":"Gastroenterol Hepatol"}],"container-title":["American Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/ajg2010125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010125","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/ajg2010125.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.ovid.com\/00000434-201006000-00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T13:34:11Z","timestamp":1786541651000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000434-201006000-00003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1038\/ajg.2010.125","relation":{},"ISSN":["0002-9270"],"issn-type":[{"value":"0002-9270","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}